Back to Search
Start Over
Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
- Source :
-
Scandinavian journal of infectious diseases [Scand J Infect Dis] 1997; Vol. 29 (1), pp. 17-22. - Publication Year :
- 1997
-
Abstract
- Patients with chronic hepatitis C respond differently when treated with interferon. We randomized 116 patients with chronic hepatitis C in order to compare two dosage regimens of recombinant interferon alpha 2a:3 MIU x 3 per week for 6 months (arm A) or 6 MIU x 3 per week for 3 months and then 3 MIU x 3 per week for 3 months (arm B). There were no significant differences concerning outcome between the two dose regimens: sustained clearance of HCV viremia 6 months after the end of treatment was obtained in 12/59 (20%) in group A compared with 18/57 (32%) in group B (p = 0.24). In patients with genotype 1a, 4/31 (13%), in genotype 1b, none of 9 (0%), 9/15 (60%) in genotype 2, and 17/58 (29%) in genotype 3, showed sustained clearance of HCV viremia 6 months after the end of treatment (p = 0.002). In a stepwise logistic regression analysis, only pretreatment viral load (p = 0.0001), genotype (p = 0.001) and age (p = 0.04) were identified as independent predictors of sustained clearance of HCV viremia. Liver histology as assessed by Knodell index was significantly improved in patients with sustained HCV RNA response 6 months after the end of treatment (5.2 +/- 2.2 vs 2.6 +/- 2.2, p < 0.001), but not in responders with relapse or in non-responders. In conclusion, stepwise logistic regression analysis showed that viral load, HCV genotype and age were the only independent predictors for sustained HCV RNA response.
- Subjects :
- Age Factors
Alanine Transaminase blood
Antiviral Agents administration & dosage
Chi-Square Distribution
Chronic Disease
Female
Genotype
Hepacivirus genetics
Hepatitis C virology
Humans
Interferon alpha-2
Interferon-alpha administration & dosage
Liver pathology
Logistic Models
Male
Norway
Odds Ratio
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
RNA, Viral blood
Recombinant Proteins
Treatment Outcome
Viral Load
Viremia therapy
Antiviral Agents therapeutic use
Hepatitis C therapy
Interferon-alpha therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0036-5548
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scandinavian journal of infectious diseases
- Publication Type :
- Academic Journal
- Accession number :
- 9112292
- Full Text :
- https://doi.org/10.3109/00365549709008658